ProfileGDS5678 / 1453801_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 48% 47% 47% 45% 46% 48% 47% 46% 45% 46% 47% 45% 47% 47% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.1842448
GSM967853U87-EV human glioblastoma xenograft - Control 23.0944447
GSM967854U87-EV human glioblastoma xenograft - Control 33.0960347
GSM967855U87-EV human glioblastoma xenograft - Control 42.989445
GSM967856U87-EV human glioblastoma xenograft - Control 53.0223346
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2397948
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1911247
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.0653346
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0410345
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0594246
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0931447
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0281445
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.1136147
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0931547